N-Nitroso Belumosudil Impurity 1 is a potential genotoxic impurity formed during the synthesis or degradation of Belumosudil.

Used in nitrosamine risk assessment studies to:

• Identify and evaluate possible contamination risks

• Support impurity profiling under ICH M7 and regulatory guidance on nitrosamines

Used as a reference standard to develop ultra-sensitive detection methods for nitrosamines, including:

• LC-MS/MS

• GC-MS

• UPLC with UV or MS detection

Enables validation of:

• Specificity between Belumosudil and nitroso impurities

• LOD/LOQ at parts-per-billion (ppb) level

• Accuracy and robustness for trace-level impurity detection

Required in regulatory filings to demonstrate nitrosamine control for:

• USFDA, EMA, MHRA, and CDSCO

• Included in ANDA, DMF, and CTD Module 3

Supports documentation for:

• Acceptable intake (AI) limits

• Control strategies and risk mitigation

Utilized in stress testing and forced degradation studies to:

• Evaluate the formation of N-Nitroso Belumosudil Impurity 1

• Understand degradation pathways under conditions like high heat, nitrite exposure, or low pH

Assists in defining shelf-life stability and packaging requirements

Used in routine QC labs to:

• Monitor and ensure the impurity is below regulatory thresholds (often <18 ng/day intake)

• Maintain product safety, purity, and compliance across production batches

Involved in genotoxicity studies and QSAR modeling to assess:

• Potential carcinogenicity

• DNA-reactivity profiles

Helps in determining if impurity qualifies for threshold of toxicological concern (TTC) exemption or requires further toxicological qualification

Belumosudil-D7 is commonly used as a stable-isotope labeled internal standard for the quantification of Belumosudil in biological samples.

Supports development of LC-MS/MS bioanalytical methods for:

• Pharmacokinetic (PK) studies

• Drug monitoring in plasma, serum, or urine

• Toxicokinetic profiling

Facilitates accurate tracking of drug absorption, distribution, metabolism, and excretion (ADME).

Used in:

• Metabolic stability assays

• Mass balance studies

• Bioavailability assessments in preclinical and clinical trials

Helps distinguish the parent drug (Belumosudil) from its metabolites during metabolic profiling.

Enables precise quantification by minimizing variability due to matrix effects in complex biological samples.

Employed in tracer studies to investigate Belumosudil’s metabolic fate without interfering with the native drug’s pharmacodynamics.

Useful for identifying biotransformation pathways and rate-limiting steps in drug metabolism.

Used for instrument calibration and validation in tandem mass spectrometry workflows.

Ensures high sensitivity and accuracy in detecting low concentrations of Belumosudil during method validation.

Supports studies evaluating enzyme inhibition or induction, especially related to cytochrome P450 isoforms or UGT enzymes.

Assists in assessing the drug-drug interaction (DDI) potential of Belumosudil via isotope-labeled kinetic models.

O-Dealkylated Belumosudil is a process-related or degradation impurity of the ROCK2 inhibitor Belumosudil.

Used to identify and quantify this impurity in the active pharmaceutical ingredient (API) and its formulations.

Ensures product purity and safety according to regulatory standards.

Serves as a reference standard in the development of stability-indicating analytical methods, including:

• HPLC

• UPLC

• LC-MS/MS

Enables validation of key method parameters like:

• Specificity

• LOD (Limit of Detection) and LOQ (Limit of Quantification)

• Linearity, precision, and accuracy

Supports documentation required for:

• ICH Q3A/B impurity qualification

• ANDA, DMF, and CTD submissions to regulatory authorities like FDA, EMA, etc.

Ensures impurity levels are within acceptable daily intake (ADI) thresholds.

Used in forced degradation testing to understand how Belumosudil degrades under:

• Acidic/basic pH

• Oxidative stress

• Light and thermal exposure

Helps map the degradation pathway and determine shelf life of the drug product.

Applied in routine batch analysis and in-process quality checks to ensure:

• Consistent impurity profiles

• Compliance with established specifications

Utilized in R&D for:

• Synthesis optimization to reduce impurity formation

• Structural characterization studies

• Supporting impurity identification during drug formulation development

N-Nitroso Belumosudil is a potential nitrosamine impurity formed during the synthesis or degradation of Belumosudil.

Used in impurity profiling to:

• Detect trace levels of nitrosamines

• Assess risk based on structure–activity relationships (SAR) and toxicological thresholds

Essential in developing sensitive and specific analytical methods (often at parts-per-billion levels), including:

• LC-MS/MS

• GC-MS

• UPLC

Supports validation of:

• LOD/LOQ (extremely low detection limits)

• Precision, accuracy, and specificity for nitrosamine detection

Required for compliance with:

• ICH M7 guidelines on control of mutagenic impurities

• USFDA, EMA, and CDSCO nitrosamine risk assessment frameworks

Supports submission of:

• Risk mitigation strategies

• Control thresholds (typically in the nanogram range/day)

Used in forced degradation studies to evaluate nitrosamine formation under various stress conditions:

• Heat, pH, light, and nitrosating agents

Helps determine:

• Stability profile of Belumosudil

• Storage and packaging precautions

Investigated in toxicological research due to the potential mutagenic and carcinogenic nature of nitrosamines.

Supports determination of:

• Acceptable intake limits (AI)

• Structure-based toxicity prediction models (QSAR)

Used by QC laboratories and API manufacturers to ensure:

• Nitrosamine impurities are controlled well below regulatory limits

• Batch-to-batch safety and process optimization to prevent impurity formation

Belumosudil Mesylate is the mesylate salt form of Belumosudil, a selective ROCK2 inhibitor.

Approved by the U.S. FDA for treating chronic GVHD in patients who have failed at least two prior lines of systemic therapy.

Modulates immune response and reduces tissue inflammation and fibrosis.

Plays a key role in the research of immune system regulation.

Inhibits Rho-associated coiled-coil-containing protein kinase 2 (ROCK2), affecting:

• T-cell activation

• Cytokine production (e.g., IL-17, IL-21, IFN-γ)

Explored in autoimmune and inflammatory disease models.

Investigated for its potential in treating organ fibrosis, including:

• Lung fibrosis

• Liver fibrosis

• Kidney inflammation

Its anti-fibrotic and anti-inflammatory actions make it valuable for preclinical and translational studies.

Used as a reference standard in drug development and manufacturing:

• Assay development

• Stability testing

• Impurity profiling

• Pharmacokinetic and bioequivalence studies

Under evaluation for potential use in hematological malignancies and solid tumors, due to its immune pathway modulation.

Supports clinical and preclinical studies related to:

• Tumor microenvironment

• T-cell exhaustion reversal

Used in the development of oral formulations for Belumosudil-based therapeutics.

Essential in:

• Quality control testing

• Batch release of final products

• Formulation stability studies

Belumosudil Metabolite KD025M2 is a primary in vivo metabolite of Belumosudil.

Used in ADME (Absorption, Distribution, Metabolism, and Excretion) studies to:

• Investigate metabolic pathways

• Understand bioavailability and systemic exposure

• Evaluate metabolite-to-parent drug ratios

Serves as a reference standard in developing LC-MS/MS methods for quantifying KD025M2 in biological matrices (plasma, serum, urine).

Supports:

• Pharmacokinetic profiling

• Metabolite monitoring in clinical studies

• Mass balance studies in drug trials

Assists in determining if KD025M2 requires qualification under ICH M3 and ICH M7 guidelines.

Helps evaluate:

• Toxicological relevance of circulating metabolites

• Safety thresholds for active or potentially reactive metabolites

Used to meet global regulatory expectations in:

• Investigational New Drug (IND) applications

• Abbreviated New Drug Applications (ANDA)

• Common Technical Documents (CTD Module 5)

Ensures that human metabolites are characterized and controlled appropriately

Employed in in vitro and in vivo degradation studies to:

• Evaluate the stability of Belumosudil and its metabolic conversion

• Identify potential transformation products during storage or metabolism

Supports therapeutic drug monitoring (TDM) and biomarker studies in clinical trials.

Helps correlate exposure-response relationships between the metabolite and clinical outcomes (e.g., immune modulation).

Belumosudil Impurity 3 is a recognized process-related or degradation impurity of the API Belumosudil (a ROCK2 inhibitor used in chronic GVHD treatment).

It is used to identify, quantify, and monitor trace-level impurities during drug development and manufacturing.

Employed in the development and validation of stability-indicating methods using:

• HPLC

• LC-MS/MS

• UPLC

Supports key validation parameters such as:

• Specificity for impurity separation

• LOD/LOQ (Limit of Detection/Quantification)

• Linearity, accuracy, and precision

Helps meet global regulatory guidelines, including:

• ICH Q3A/B for impurity control

• Required in ANDA, DMF, and CTD filings

Assists in justifying impurity limits and supports toxicological risk assessments

Used in forced degradation testing to evaluate:

• The formation of Belumosudil Impurity 3 under stress conditions (e.g., light, heat, pH, oxidation)

Helps define the degradation profile and shelf life of the finished drug product

Integrated into batch release and in-process quality checks to ensure impurity levels are:

• Within regulatory thresholds

• Consistent across production batches

Utilized by R&D and CRO laboratories to:

• Analyze synthetic route optimization

• Investigate mechanisms of impurity formation

• Conduct reference standard comparison for impurity profiling

Belumosudil Impurity 2 is a known process-related or degradation impurity of the drug Belumosudil, a ROCK2 inhibitor.

Used to detect, identify, and quantify impurities in:

• Belumosudil Active Pharmaceutical Ingredient (API)

• Belumosudil drug formulations (oral tablets, capsules)

Plays a critical role in developing and validating stability-indicating analytical methods, such as:

• HPLC

• UPLC

• LC-MS/MS

Ensures accurate detection of Impurity 2 by validating:

• Specificity (clear separation from API)

• Limit of Detection (LOD) and Limit of Quantification (LOQ)

• Linearity, accuracy, and precision

Supports documentation for:

• ICH Q3A/B impurity qualification guidelines

• Regulatory filings like ANDA, DMF, and CTD for global markets

Helps justify and control Belumosudil impurity levels within acceptable thresholds

Used to study impurity formation under forced degradation conditions such as:

• Oxidation, hydrolysis, heat, and light exposure

Assists in defining the stability profile and shelf life of Belumosudil drug products

Applied during batch release, in-process testing, and final product quality checks

Ensures that Impurity 2 levels remain within regulatory limits, maintaining drug safety and consistency

Utilized by pharmaceutical R&D teams and CROs for:

• Studying synthetic route optimization

• Investigating impurity mechanisms

• Supporting impurity mapping and control strategies in early development stages